Skip to main content
. 2018 Jul 17;17(10):1245–1254. doi: 10.1080/15384101.2018.1471317

Figure 6.

Figure 6.

ZEB1-AS1 is a direct target of miR-181a-5p. (a) Schematic illustration of the predicted ZEB1-AS1/miR-181a-5p binding sites and the mutations in these binding sequences. (b) Luciferase assays in 293 T cells transfected with wild-type or mutant ZEB1-AS1 and miR-181a-5p (n = 6, *P < 0.05 vs NC). (c) The amount of ZEB1-AS1 and miR-181a-5p bound to Ago2 or IgG was measured by RT–qPCR in the presence of a miR-181a-5p inhibitor or negative control (n = 6, *P < 0.05 vs NC). (d-e) Western blotting was used to detect levels of β-catenin, TCF4, cyclin D1, Myc, and MMP-7 in LOVO cells after transfection with miR-181a-5p mimic or ZEB1-AS1-siRNAs or co-transfection with miR-181a-5p inhibitor and ZEB1-AS1-siRNAs (n = 6; *P < 0.05 vs NC; #P < 0.05 vs ZEB1-AS1-siRNAs). (f-g) Expression of miR-181a-5p targets in RKO cells transfected with a ZEB1-AS1 expression plasmid or co-transfected with a ZEB1-AS1 expression plasmid and a miR-181a-5p mimic (n = 6; *P < 0.05 vs NC; #P < 0.05 vs miR-181a-5p).